CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 44 enrolled
Drug / intervention
Trospium Chloride (Sanctura XR®) +1 moredrug
Likely dose
Trospium Chloride (Sanctura XR®) 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00986401
NCT00986401Phase 1Completed
CompareCT.gov

Safety and Tolerability of Trospium Chloride Metformin Hydrochloride in Healthy Subjects

Allergan·interventional·Posted Sep 30, 2009·Updated Dec 19, 2011

In Brief

A Phase 1 clinical trial evaluating Trospium Chloride (Sanctura XR®) and Metformin hydrochloride (Glucophage®) for Healthy. Completed, enrolled 44 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate the safety and tolerability of trospium chloride (Sanctura XR™) and metformin hydrochloride (Glucophage) when co-administered.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 30, 2009
Enrollment StartOct 1, 2009
Primary CompletionNov 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 16.8 years ago

Interventions

Trospium Chloride (Sanctura XR®)drug

extended release, 60 mg, oral daily

Metformin hydrochloride (Glucophage®)drug

immediate release, 500mg